Ischemic Stroke After Anticoagulation Discontinuation Following Apparent Resolution of Left Ventricular Thrombus: A Case Report
Abstract
Left ventricular thrombus (LVT) is a serious complication of ischemic cardiomyopathy and anterior myocardial infarction, with an important risk of systemic embolism and stroke. Transthoracic echocardiography is commonly used for diagnosis and follow-up, but it may fail to detect residual thrombus in some high-risk patients. We report the case of a 64-year-old Saudi man with diabetes mellitus, hypertension, severe ischemic cardiomyopathy, and a known left ventricular apical thrombus after prior anterior myocardial infarction and multivessel coronary intervention. He was treated with apixaban and guideline-directed medical therapy. Follow-up echocardiography later showed no visible thrombus, and anticoagulation was discontinued. However, the patient subsequently developed an ischemic stroke with prolonged disability. This case highlights the diagnostic uncertainty that may remain after apparent resolution of LVT on echocardiography and emphasizes the need for careful clinical judgment before stopping anticoagulation in patients with severe left ventricular dysfunction and high embolic risk. Advanced imaging, such as cardiac magnetic resonance imaging or contrast-enhanced echocardiography, may be considered when diagnostic certainty is required.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.